264 related articles for article (PubMed ID: 27739361)
21. Nanocarriers Based Anticancer Drugs: Current Scenario and Future Perceptions.
Raj R; Mongia P; Kumar Sahu S; Ram A
Curr Drug Targets; 2016; 17(2):206-28. PubMed ID: 26201484
[TBL] [Abstract][Full Text] [Related]
22. Nanomedicine: An effective tool in cancer therapy.
Aftab S; Shah A; Nadhman A; Kurbanoglu S; Aysıl Ozkan S; Dionysiou DD; Shukla SS; Aminabhavi TM
Int J Pharm; 2018 Apr; 540(1-2):132-149. PubMed ID: 29427746
[TBL] [Abstract][Full Text] [Related]
23. Nanoparticles for delivery of chemotherapeutic agents to tumors.
Vijayaraghavalu S; Raghavan D; Labhasetwar V
Curr Opin Investig Drugs; 2007 Jun; 8(6):477-84. PubMed ID: 17621878
[TBL] [Abstract][Full Text] [Related]
24. A novel progress of drug delivery system for organelle targeting in tumour cells.
He Z; Zhang Y; Khan AR; Ji J; Yu A; Zhai G
J Drug Target; 2021 Jan; 29(1):12-28. PubMed ID: 32698651
[TBL] [Abstract][Full Text] [Related]
25. Drug targeting strategies in cancer treatment: an overview.
Arias JL
Mini Rev Med Chem; 2011 Jan; 11(1):1-17. PubMed ID: 21235512
[TBL] [Abstract][Full Text] [Related]
26. Drug Delivery Systems of Natural Products in Oncology.
Colone M; Calcabrini A; Stringaro A
Molecules; 2020 Oct; 25(19):. PubMed ID: 33036240
[TBL] [Abstract][Full Text] [Related]
27. Tailoring of physicochemical properties of nanocarriers for effective anti-cancer applications.
Chakraborty S; Dhakshinamurthy GS; Misra SK
J Biomed Mater Res A; 2017 Oct; 105(10):2906-2928. PubMed ID: 28643475
[TBL] [Abstract][Full Text] [Related]
28. Methotrexate-based amphiphilic prodrug nanoaggregates for co-administration of multiple therapeutics and synergistic cancer therapy.
Hou M; Gao YE; Shi X; Bai S; Ma X; Li B; Xiao B; Xue P; Kang Y; Xu Z
Acta Biomater; 2018 Sep; 77():228-239. PubMed ID: 30006314
[TBL] [Abstract][Full Text] [Related]
29. Circumventing tumor resistance to chemotherapy by nanotechnology.
Liang XJ; Chen C; Zhao Y; Wang PC
Methods Mol Biol; 2010; 596():467-88. PubMed ID: 19949937
[TBL] [Abstract][Full Text] [Related]
30. Nanotechnology-based intelligent drug design for cancer metastasis treatment.
Gao Y; Xie J; Chen H; Gu S; Zhao R; Shao J; Jia L
Biotechnol Adv; 2014; 32(4):761-77. PubMed ID: 24211475
[TBL] [Abstract][Full Text] [Related]
31. Nanomedicine in cancer treatment.
Yih TC; Wei C
Nanomedicine; 2005 Jun; 1(2):191-2. PubMed ID: 17292078
[No Abstract] [Full Text] [Related]
32. Intratumoral Pharmacokinetics: Challenges to Nanobiomaterials.
Al-Abd AM; Al-Abbasi FA; Torchilin VP
Curr Pharm Des; 2015; 21(22):3208-14. PubMed ID: 26027565
[TBL] [Abstract][Full Text] [Related]
33. Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system.
Kibria G; Hatakeyama H; Harashima H
Arch Pharm Res; 2014 Jan; 37(1):4-15. PubMed ID: 24272889
[TBL] [Abstract][Full Text] [Related]
34. Targeted delivery of etoposide to cancer cells by folate-modified nanostructured lipid drug delivery system.
Zhang S; Lu C; Zhang X; Li J; Jiang H
Drug Deliv; 2016 Jun; 23(5):1838-45. PubMed ID: 26879035
[TBL] [Abstract][Full Text] [Related]
35. Classification of stimuli-responsive polymers as anticancer drug delivery systems.
Taghizadeh B; Taranejoo S; Monemian SA; Salehi Moghaddam Z; Daliri K; Derakhshankhah H; Derakhshani Z
Drug Deliv; 2015 Feb; 22(2):145-55. PubMed ID: 24547737
[TBL] [Abstract][Full Text] [Related]
36. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
Khaitan D; Reddy PL; Ningaraj N
Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
[TBL] [Abstract][Full Text] [Related]
37. Challenges and Opportunities from Basic Cancer Biology for Nanomedicine for Targeted Drug Delivery.
Xie X; Zhang Y; Li F; Lv T; Li Z; Chen H; Jia L; Gao Y
Curr Cancer Drug Targets; 2019; 19(4):257-276. PubMed ID: 29956629
[TBL] [Abstract][Full Text] [Related]
38. Precise design strategies of nanomedicine for improving cancer therapeutic efficacy using subcellular targeting.
Fu X; Shi Y; Qi T; Qiu S; Huang Y; Zhao X; Sun Q; Lin G
Signal Transduct Target Ther; 2020 Nov; 5(1):262. PubMed ID: 33154350
[TBL] [Abstract][Full Text] [Related]
39. Dodging drug-resistant cancer with diamonds.
Merkel TJ; DeSimone JM
Sci Transl Med; 2011 Mar; 3(73):73ps8. PubMed ID: 21389261
[TBL] [Abstract][Full Text] [Related]
40. Mitochondrial-targeted penetrating peptide delivery for cancer therapy.
Wu J; Li J; Wang H; Liu CB
Expert Opin Drug Deliv; 2018 Oct; 15(10):951-964. PubMed ID: 30173542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
